



NACFC 2020 CONTINUING EDUCATION GUIDE

The Cystic Fibrosis Foundation welcomes you to the 34TH Annual North American Cystic Fibrosis Conference.

NACFC is the largest gathering of cystic fibrosis professionals in the world and provides superior continuing medical education and a multi-disciplinary approach to advancement of CF research, treatments, and care.

Target Audience

NACFC has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Learning Goal/Purpose

The learning goal/purpose of this conference is to enable caregivers the opportunity to receive the most current and up-to-date information on the diagnosis and management of cystic fibrosis and to learn strategies for improving outcomes for patients.

Educational Objectives

After completing this program, participants should be better able to:

- Discuss CF research protocols with their patients and families.
- Apply one or more quality improvement projects to their practice to improve patient outcomes.
- Employ strategies to improve patient and family adherence to treatment recommendations.
- Use infection control recommendations in their practice.
- Apply CF Foundation practice guidelines.

Statement of Need/Program Overview

This program has been designed to educate physicians and allied health professionals on recent advances in basic and clinical research related to CF and to discuss issues, problems, and new approaches to the diagnosis and clinical management of CF patients. The conference is directed toward physicians, other healthcare professionals, and researchers involved in the CF field. The portions of the meeting focused on research advances are intended to educate medical professionals on the general approaches used, interpretation of data, future research directions, and current and future impact on clinical practice. Clinically oriented sessions will encompass presentation/discussion of problems and issues, recent advances, and application to multidisciplinary management of patients and interactions with family members.

Information on CE credits for on-demand content is available after the At-A-Glance section of this guide.

To Claim Credits, Certificates of Attendance, and Transcripts visit the [CE Portal](#).

Genetic Counselors

This year, genetic counselors will be able to claim Category 2 CEUs.

To claim CEUs for NACFC 2020, genetic counselors should visit [NSGC.org](https://www.nsgc.org), log in to the CEU portal there and complete the application. The application for Category 2 CEUs must be completed within **90 days** of completing the educational activity.

Nurses

Medical Education Resources (MER) is accredited as a provider of nursing continuing education by the American Nurses Credentialing Center's Commission on Accreditation.

The CE activity provides up to **18** contact hours of continuing nursing education. Provider approved by the California Board of Registered Nursing, Provider Number 12299, for up to **18** contact hours.

Nutritionists/Dieticians

To claim credits for the live virtual NACFC 2020, the Commission on Dietetic Regulation (CDR) does not require prior approval. To claim credits from CDR, log the program in your Step 4: Activity Log under Activity Type 170 - Lecture/Seminar/Teleseminar/Webinar, and claim 1 CPEU for every 1 contact hour spent during the activity. Please also retain for your documentation either a certificate of completion or an agenda/timing outline which accurately reflects the number of contact hours spent completing this activity.

When counting contact hours, please be certain not to include time taken for breaks, meals, or exams. Only time spent in lecture/seminar may be counted (from [CDR FAQ](#)).

Pharmacists

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates the continuing education activity for **18** contact hours of the Accreditation Council for Pharmacy Education.

Universal Program Number: 0816-9999-20-161-L01-P. This activity is certified as knowledge-based CPE.

Physical Therapists

Certificate of attendance and session transcript can be obtained for this activity.

Physicians

Medical Education Resources designates this live activity for a maximum of **18 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

The AAPA accepts certificates of participation for educational activities certified for Category 1 credit for the AOACCME, prescribed credit for the AAFP and *AMA PRA Category 1 Credit™* from organizations accredited by the Accreditation Council for Continuing Medical Education (ACCME) or a recognized state medical society. Physician assistants may receive a maximum of **18** *AMA PRA Category 1 Credits™* for completing this activity.

Psychiatrists

Psychiatrists may receive a maximum of **18** *AMA PRA Category 1 Credits™* for completing this activity.

Psychologists

This activity is being co-sponsored by the Maryland Psychological Association and the Cystic Fibrosis Foundation. The Maryland Psychological Association is approved by the American Psychological Association to offer continuing education for psychologists. The Maryland Psychological Association maintains responsibility for the program and its content.

NACFC 2020 has been approved for **7.5** contact hours.

Respiratory Therapists

NACFC 2020 has been approved for a maximum of **14.82** contact hours of Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care.

Social Workers

NACFC 2020 is approved by the National Association of Social Workers for **14.5** contact hours (Approval #886552784-2218)

Disclaimer and Disclosure of Conflicts of Interest

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources or the Cystic Fibrosis Foundation. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources or the CFF. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Conflicts of Interests

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. Disclosures of conflicts of interest from the speakers will be provided at the start of every session. MER and CFF content managers have no financial relationships with commercial interests to disclose. Speakers will provide disclosure information in their slides at the beginning of their presentations

Wednesday, October 21, 2020												
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT	
10:00 AM - 11:20 AM	S01-- *CLIN: Science of COVID-19 Infections & Treatments in CF	Symposium	X	X	X	X	X		X	X	X	
2:15 PM- 3:15 PM	Discussion: S01-- *CLIN: Science of COVID-19 Infections & Treatments in CF	Discussion	X	X	X	X	X		X	X	X	
10:00 AM - 11:20 AM	S02--PTC-APP&D-NT: Novel Nucleic Acid Strategies to Treat the Fundamental CF Defect	Symposium	X	X	X					X		
2:15 PM- 3:15 PM	Discussion: S02--PTC-APP&D-NT: Novel Nucleic Acid Strategies to Treat the Fundamental CF Defect	Discussion	X	X	X					X		
10:00 AM - 11:20 AM	S03--PT&RT: The PT/RT Year in Review: Where Are We & Where Are We Going?	Symposium	X	X	X	X			X	X	X	
2:15 PM- 3:15 PM	Discussion: S03--PT&RT: The PT/RT Year in Review: Where Are We & Where Are We Going?	Discussion	X	X	X	X			X	X	X	
10:00 AM - 11:20 AM	S04--CFTR: CFRD Unresolved Clinical Questions	Symposium	X	X	X	X	X		X	X	X	
2:15 PM- 3:15 PM	Discussion: S04--CFTR: CFRD Unresolved Clinical Questions	Discussion	X	X	X	X	X		X	X	X	
11:30 AM - 12:50 PM	S05--INF/MIC: The Epidemiology & Management of Nontuberculous Mycobacteria Infection	Symposium	X	X	X	X				X		
3:30 PM - 4:30 PM	Discussion: S05--INF/MIC: The Epidemiology & Management of Nontuberculous Mycobacteria Infection	Discussion	X	X	X	X				X		

Wednesday, October 21, 2020											
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT
11:30 AM - 12:50 PM	S06--PTC: State of the Art: Gene Editing Technologies for Understanding & Treatment of Disease	Symposium	X	X	X					X	
3:30 PM - 4:30 PM	S06--PTC: State of the Art: Gene Editing Technologies for Understanding & Treatment of Disease	Discussion	X	X	X					X	
11:30 AM - 12:50 PM	S07--SW/PSYCH-NRS: *Culturally Competent CF Care	Symposium	X	X	X	X	X	X	X	X	X
3:30 PM - 4:30 PM	Discussion: S07--SW/PSYCH-NRS: *Culturally Competent CF Care	Discussion	X	X	X	X	X	X	X	X	X
11:30 AM - 12:50 PM	S08--CLIN-NRS-SW/PSYCH: Addressing Women's Health in CF	Symposium	X	X	X	X	X	X	X	X	X
3:30 PM - 4:30 PM	Discussion: S08--CLIN-NRS-SW/PSYCH: Addressing Women's Health in CF	Discussion	X	X	X	X	X	X	X	X	X
1:00 PM - 2:00 PM	P1--*Laying the Foundation for the Path to a Cure: The Fundamentals of Genetic-Based Therapies	Plenary	X	X	X	X	X	X	X	X	X
4:45 PM - 5:30 PM	Top 3 Abstracts in Airways Physiology, Pathophysiology & Defense	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Nursing	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Path to a Cure	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Pharmacy	Workshop	X	X	X					X	

Thursday, October 22, 2020											
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT
10:00 AM - 11:20 AM	S09--GMS-NT-PTC: CFTR-Directed Therapy Experiences in Animal Models	Symposium	X	X	X					X	
2:15 PM - 3:15 PM	Discussion: S09--GMS-NT-PTC: CFTR-Directed Therapy Experiences in Animal Models	Discussion	X	X	X					X	
10:00 AM - 11:20 AM	S10--NT: CFTR Modulators: What We Are Learning	Symposium	X	X	X	X			X	X	X
2:15 PM - 3:15 PM	Discussion: S10--NT: CFTR Modulators: What We Are Learning	Discussion	X	X	X	X			X	X	X
10:00 AM - 11:20 AM	S11--PT&RT: PT/RT Issues Across the Adult Lifespan: Transitions From Teens to the Elderly & Everything in Between	Symposium	X	X	X	X			X	X	X
2:15 PM - 3:15 PM	Discussion: S11--PT&RT: PT/RT Issues Across the Adult Lifespan: Transitions From Teens to the Elderly & Everything in Between	Discussion	X	X	X	X			X	X	X
10:00 AM - 11:20 AM	S12--NRS: Advance Practice Provider Huddle Evolving APP Practice in the age of COVID-19 & Highly Effective Modulator Therapy	Symposium	X	X	X	X			X	X	X
2:15 PM - 3:15 PM	Discussion: S12--NRS: Advance Practice Provider Huddle Evolving APP Practice in the age of COVID-19 & Highly Effective Modulator Therapy	Discussion	X	X	X	X			X	X	X

Thursday, October 22, 2020											
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT
11:30 AM - 12:50 PM	S13--CFTR: Ion Transport in CF Pathology	Symposium	X	X	X					X	
3:30 PM - 4:30 PM	Discussion: S13--CFTR: Ion Transport in CF Pathology	Discussion	X	X	X					X	
11:30 AM - 12:50 PM	S14--INF/MIC: Bacterial Adaptation & Persistence	Symposium	X	X	X	X				X	
3:30 PM - 4:30 PM	Discussion: S14--INF/MIC: Bacterial Adaptation & Persistence	Discussion	X	X	X	X				X	
11:30 AM - 12:50 PM	S15--CLIN: Pro Con Debate: Modulator Therapies	Symposium	X	X	X	X			X	X	X
3:30 PM - 4:30 PM	Discussion: S15--CLIN: Pro Con Debate: Modulator Therapies	Discussion								X	
1:00 PM - 2:00 PM	P2--*Defining the New CF in the Era of Highly Effective Modulators	Plenary	X	X	X	X	X	X	X	X	X
3:30 PM - 4:30 PM	SSC--Special Session: Discussion of CFTR Cases	Special Session	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in CFTR	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Clinical	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Genetics & Model Systems	Workshop	X	X	X					X	
4:45 PM - 5:30 PM	Top 3 Abstracts in Social Work/Psychosocial	Workshop	X	X	X		X			X	

Friday, October 23, 2020											
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT
10:00 AM - 11:20 AM	S16--NTR-CLIN-PT&RT: An Unexpected Problem: Weight Management in CF	Symposium	X	X	X	X			X	X	X
11:30 AM - 12:30 PM	Discussion: S16--NTR-CLIN-PT&RT: An Unexpected Problem: Weight Management in CF	Discussion	X	X	X	X			X	X	X
10:00 AM - 11:20 AM	S17--U&C-CLIN-SW/PSYCH: Lessons From the COVID-19 Pandemic: Innovative Approaches to Health Care Access & Clinical Care	Symposium	X	X	X	X	X	X	X	X	X
11:30 AM - 12:30 PM	Discussion: S17--U&C-CLIN-SW/PSYCH: Lessons From the COVID-19 Pandemic: Innovative Approaches to Health Care Access & Clinical Care	Discussion	X	X	X	X	X	X	X	X	X
10:00 AM - 11:20 AM	S18--CLIN-INF/MIC: Targeting Infection During Pulmonary Exacerbation Management	Symposium	X	X	X	X				X	
11:30 AM - 12:30 PM	Discussion: S18--CLIN-INF/MIC: Targeting Infection During Pulmonary Exacerbation Management	Discussion	X	X	X	X				X	
10:00 AM - 11:20 AM	S19--PHARM: Partnering With Your Pharmacy Team - Prescription for Success	Symposium	X	X	X	X			X	X	
11:30 AM - 12:30 PM	Discussion: S19--PHARM: Partnering With Your Pharmacy Team - Prescription for Success	Discussion	X	X	X	X			X	X	
1:00 PM - 1:45 PM	Top 3 Abstracts in Infection/Microbiology	Workshop	X	X	X					X	

Friday, October 23, 2020											
Time	Session Title	Type	CME	ANCC	Pharm	RT	SW	Psych	NTR	GC	PT
1:00 PM - 1:45 PM	Top 3 Abstracts in New Therapies	Workshop	X	X	X					X	
1:00 PM - 1:45 PM	Top 3 Abstracts in Nutrition	Workshop	X	X	X					X	
1:00 PM - 1:45 PM	Top 3 Abstracts in Physical & Respiratory Therapy	Workshop	X	X	X					X	
1:00 PM - 1:45 PM	Top 3 Abstracts in Utilization & Coverage	Workshop	X	X	X					X	
2:00 PM - 3:00 PM	P3--*Advancing the GI Frontier for People With CF	Plenary	X	X	X	X	X	X	X	X	X

NACFC 2020 Enduring Activities

This year, the Cystic Fibrosis Foundation is offering enduring activities prior to the live virtual NACFC 2020.

An activity is considered enduring when it is recorded and available for a specified period. It does not have a specific time or location required for participation. Participants can select which activities to view and when to complete the activity during the available period.

The following is a list of the enduring activities being offered and information regarding obtaining continuing education credits for each.

DG01 CLIN: Hot Topics and Trends in Clinical Research

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This activity will cover topics useful for Research Coordinators and Research Teams. The focus will be on how to stay organized and improve team communication, how to be compliant with the help of your friends and the RC Tool Box, and how to translate lessons learned from the COVID-19 pandemic in the future.

Educational Objectives

1. Discuss lessons learned from the COVID-19 pandemic that impact the future.
2. Identify ways to keep your team in touch and organized.
3. Design processes with your team to ensure compliance without recreating the wheel.

Faculty

Jane Vroom CCRC

Zachary Messer M.P.H.

Candy Schmoll B.S.N., R.N.

Danielle Wolfe B.S.N., M.S., R.N.

Adrienne DeRicco BSN,R.N., CCRC

Brendan Klein MPH, CCRP

Jenna Bucher B.S.

Jeannette Dingedine M.B.A.

Matt Myers B.A., CCRA

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-143-H04-P)

This activity is certified as Knowledge-based CPE.

DG02 CLIN--NTR: Optimizing CF Nutrition Care in a New Era

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

The management of nutrition in CF is evolving at an extremely rapid pace. The success of CFTR modulators warrants a need to re-evaluate global nutritional recommendations for individuals with CF. In addition, COVID-19 has necessitated new virtual approaches to assess nutrition status in patients. This session provides updates and best practices to managing CF nutrition care now and as we move forward.

Educational Objectives

1. Apply best practices in conducting virtual assessments of nutrition status.
2. Describe nutritional impact of CFTR modulators and provide practical examples of clinical nutrition strategies.
3. Incorporate evidence-based nutrition guidelines from various societies into practice.

Faculty

Jessica Alvarez Ph.D., R.D.

Catherine McDonald Ph.D., R.D.N., C.S.P.

Lucy Gettle M.S., R.D.N., CNSC

Amanda Leonard M.P.H., R.D., C.D.C.E.S.

Dr. Susannah King Ph.D., M.P.H.

Dimitri Declercq M.Sc.

Julianna Bailey M.S., R.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-201-H01-P)

This activity is certified as Knowledge-based CPE.

DG06 PHARM: Challenging Pharmacotherapy Issues Across the CF Continuum of Care

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This session will focus on various challenging pharmacotherapy issues encountered by CF pharmacy practitioners. These issues include management of acute pulmonary exacerbation's of MDR organisms, CF patient transitions of care, and integrating pharmacy technicians into your CF clinic team.

Educational Objectives

1. Describe the appropriate management of acute pulmonary exacerbations of MDR organisms.
2. Explain various issues in transitions of care for CF patients.
3. Discuss issues surrounding integration of pharmacy technicians into your CF clinic team.

Faculty

Justin Moss CPHT

Rebecca Pettit Pharm.D., M.B.A.

Kathleen O'Dell CPHT

Kevin Epps Pharm.D., BCPS, BCIDP

Sabrina Sherwood PharmD

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-145-H01-P)

This activity is certified as Knowledge-based CPE

DG09 CLIN: RC Updates & Special Topics

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

CFF and TDNCC leadership will provide updates regarding tools, resources and programs pertinent to research coordinators. In addition to this, we will discuss current Network issues and how they might be addressed. Finally, case presentations will be given which will allow RCs the opportunity to examine study conduct at their site and opportunities for improvement.

Educational Objectives

1. Apply tools, resources, and programs pertinent to research coordinators.
2. Discuss current Network issues and how they might be addressed.
3. List case presentations will be given which will allow RCs the opportunity to examine study conduct at their site and opportunities for improvement.

Faculty

Lisa Bendy, B.A., R.R.T., CCRC

Patricia Burks, R.N., M.A., CCRC

Amy Hoffman M.P.H.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-146-H01-P)

This activity is certified as Knowledge-based CPE

DG11 NRS: CFRD 2.0

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

Application of the Cystic Fibrosis Foundation cystic fibrosis related diabetes (CFRD) recommendations will be reviewed. Best practices in caring for the patient with CFRD, strategies for insulin management and use of the continuous glucose monitor and insulin pump will be discussed.

Educational Objectives

1. Apply the CFF recommendations to pediatric and adult patients with CFRD.
2. State best practices for the diagnosis and management of CFRD for pediatric and adult patients.
3. Identify patients who would be most appropriate and/or benefit from the use of a continuous blood glucose monitor and insulin pump.

Faculty

Mary Ellen Corrigan M.S.N., PNP-c

Diana Dawson P.N.P., M.S.

Marisa Desimone M.D.

Krystal Kobasic B.S.N., M.S., C.D.E.

Maria Rayas M.D.

Donna Willey-Courand M.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-147-H01-P)

This activity is certified as Knowledge-based CPE

DG13 PHARM: CF Care - When There Are No Guidelines

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

Review topics that do not have hard evidence or guidance for approaching practice across an assortment of topics. Speakers will present on elexacaftor-tezacaftor-ivacaftor adverse drug events and possible management strategies as well as recommendations and implications of marijuana use in patients with CF. A panel will explain and answer questions on how their CF teams and institutions justified funding for CF Pharmacy Services. Subsession titles: (1) Elexa-Teza-Ivacaftor: What The AE? (2) CF During a Pandemic: How to Provide Pharmacy Services (3) Justification of CF Pharmacy Services –panel discussion.

Educational Objectives

1. Compare adverse drug events reported with elexacaftor-tezacaftor-ivacaftor to what was seen in the original clinical trials. Discuss possible management of adverse events.
2. Describe the delivery of pharmacy services in response to a pandemic and future implications for care.
3. Identify methods to obtain and sustain funding for pharmacy personnel dedicated to CF care.

Faculty

Megan Fleischman Pharm.D.

Caitlin Duncan CPhT

Elizabeth Autry Pharm.D., BCPPS

Lauren Kormelink Pharm.D, BCACP

Emily Dufek CPhT

Rachel Espinosa Pharm.D.

Kim Ehlert Pharm.D.

Erin McDade Pharm.D.

Jenna Faircloth PharmD

Jessica Ferdinand CPhT

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-148-H01-P) This activity is certified as Knowledge-based CPE

DG15 RT: Continuing to Bridge the Gap Between Outpatient & Inpatient CF Care

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

Providers from various disciplines discuss reducing the disparities between inpatient and outpatient CF care – how to improve communication, education of bedside providers, continuity in care and improving patient/family/caregiver satisfaction.

Educational Objectives

1. Identify potential gaps in communication.
2. Formulate problem solving strategies with colleagues from across disciplines and healthcare settings.
3. Create and implement tools to improve communication, patient care and patient/family satisfaction.

Faculty

Dawn Selhorst B.S., R.R.T.

Carolina Sprinkle R.T.

Leah Graham B.S., RRT-NPS, AE-C

Mary Gant APRN, M.S.N., R.R.T.

Kathleen Richards R.R.T.

Perdita Shook R.R.T.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-149-H01-P)

This activity is certified as Knowledge-based CPE

DG16 SW/PSYCH: The Psychosocial Implications of New Modulators

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

The impact of Trikafta and the promise it holds for so many is a multi-layered and varied experience for the CF community that will continue to unfold in the years to come. This session will overview early emerging themes of concern to the CF community. Considerations for Mental Health Coordinators/Providers and people with CF and their families as they co-navigate this new frontier will also be discussed.

Educational Objectives

1. Identify key psychosocial aspects of Trikafta from multiple perspectives
2. Describe the emerging psychopharmacological impacts of Trikafta, from "normal" to potential adverse effects
3. Identify ways in which MHCs can explore individuals' unique experiences while navigating both hope and realism in the absence of long-term outcome data

Faculty

Jamie Becker Ph.D.

Amy Mueller LCSW

Carolyn Snell Ph.D.

Meg Hall LCSW

Anna Georgiopoulos M.D.

Mary Lynn Dell M.D., D.Min.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-165-H01-P)

This activity is certified as Knowledge-based CPE

DG18 CLIN: The Role of the New TDN Clinical Research Coordinator

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This session will provide information regarding tools, resources and programs pertinent to research coordinators new to the TDN. In addition to this, we will discuss the perspective from two new coordinators and the how they have navigated orientation during this past year. The wins and challenges they have had for their orientation and learning, despite the challenges during COVID-19. We will have an experienced manager, of one of the new coordinators, provide of what makes a successful plan for a new coordinator orientation. Finally, we will summarize these experiences and provide feedback between the session participants.

Educational Objectives

1. List tools, resources and programs available to new TDN Research Coordinators.
2. Identify what type of orientation content is most beneficial for a new coordinator.
3. Describe a successful orientation plan for a new coordinator from a manager perspective.
4. Summarize the experience of research personnel both new and accomplished in measuring successful training and integration into a TDN Research Role.

Faculty

Lisa Bendy BA, RRT, CCRC
Miguel Bahena-Garcia RN

Candy Schmoll B.S.N., R.N.
Matthew Butoryak RN, CCRC

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Program Number - 0816-9999-20-151-H03-P).

This activity is certified as Knowledge-based CPE

DG19 PHARM: Impact of Pharmacy Care on Patients & Families

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 2 hours

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This session will focus on the impact of pharmacy providers on the lives of CF patients and caregivers from the perspective of CF patients.

Educational Objectives

1. Describe the impact of pharmacy in the lives of CF patients and families.
2. Discuss ways in which pharmacists and /or pharmacy technicians can improve pharmaceutical care for CF patients/caregivers.

Faculty

Jeffery Zobell Pharm.D., BCPPS

Stephanie Heuser CphT

Jennifer Hepworth N/A

Dana Snyder N/A

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 2 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 2 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-152-H01-P)

This activity is certified as Knowledge-based CPE

S20 CLIN: NRS-NT Year(s) in Review

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This activity provides an overview of recent key publications in some challenging areas of CF care.

Educational Objectives

1. Summarize recent updates in CF-related liver and bone disease.
2. Report on treatment updates with CFTR modulators.
3. Define the role of bacteriophages in CF treatment and outcomes in people with CF diagnosed with SARS-CoV-2.

Faculty

Ahmet Uluer D.O., M.P.H.

Melanie Chin M.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-153-H01-P)

This activity is certified as Knowledge-based CPE

S21CFTR: Biology Boosting CFTR Expression & Function

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This activity will discuss the current efforts and challenges associated with increasing CFTR expression and activity to provide therapeutic benefit to CF patients. The session will provide an overview of the molecular impacts of CFTR variants on protein biosynthesis, trafficking and activity, and current efforts to evaluate and expand the use of approved therapeutics.

Educational Objectives

1. Describe the molecular and cellular impacts that rare CFTR variants have on its expression and function.
2. Evaluate the use of currently approved therapeutics for correction of rare CFTR variants found in the patient population.
3. Discuss challenges associated with increasing CFTR activity in variants that are refractory to available therapeutics.

Faculty

Christine Bear Ph.D.

Patrick Thibodeau Ph.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-154-H01-P)

This activity is certified as Knowledge-based CPE

S22 NRS: Complicated Complications

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

Cystic Fibrosis (CF) is a complex multisystem disease. This session will focus on some of the complications that the CF team might need to address. Topics of Sinus Disease, Pulmonary Hypertension and Sleep Disordered breathing will be presented. Additionally, attendees can anticipate a presentation on how Palliative Care can assist with managing patients with "challenging challenges".

Educational Objectives

1. Recognize complications associated with Sinus and Pulmonary Hypertension in the CF patient.
2. Identify the strategies to manage Non-Invasive Positive Pressure Ventilation (NIPPV).
3. Describe how palliative care can assist with addressing dilemmas that the CF team encounters when caring for complex CF patients.

Faculty

Sasikumar Kilaikode M.D.

Kathryn McAndrews M.S.N., APRN

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-155-H01-P)

This activity is certified as Knowledge-based CPE

S23 PTC: Advances in Induced Pluripotent Stem Cell Technology on the Path to a Cure

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This activity will summarize the current status of translational research on CF progressing toward restoration of a functional mucociliary epithelium by cell, gene or gene-targeting therapeutic approaches with a particular focus on the application and utility of induced pluripotent stem cell technology.

Educational Objectives

1. Discuss the most current advances toward the application of induced pluripotent stem cells and their derivatives as cellular models for CF.
2. Describe recent advances in gene therapy and gene editing as therapeutic approaches for CF.
3. Evaluate the feasibility of the application of iPSC derived cells as a cellular therapy for CF.

Faculty

Amy Ryan (Firth) Ph.D.

Dr. Finn Hawkins MBBS

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-156-H01-P)

This activity is certified as Knowledge-based CPE

S24 APP&D-PTC: Leveraging Lung Biology: Gateway to Therapy for All

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

Highly effective therapies for CFTR deficiency are available for 90% of CF patients. Unfortunately, the drugs will not help all patients and there is a pressing need to address therapeutic strategies that for all individuals with CF. This symposium will address innovative treatment strategies and features of airway biology we need to understand to bring effective therapy to all.

Educational Objectives

1. Apply the various pharmacological approaches to correct CFTR function in individuals with pre-termination codon mutations.
2. Appraise the key issues that need to be addressed for CF gene therapy to become a reality.
3. Interpret the opportunities for non-CFTR therapy for all individuals with CF that stem from a better understanding of airway biology.

Faculty

Andre Cantin M.D.

Dr. Lael Yonker M.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™].

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-157-H01-P)

This activity is certified as Knowledge-based CPE

S25 CLIN: Management of GI Symptoms in CF

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

In this activity, the speakers will review up to date information regarding the evaluation, consideration, and concerns across the spectrum of medical and surgical management of common GI disorders in patients with CF, including gastroesophageal reflux, bloating, dysbiosis, meconium ileus, distal ileal obstruction syndrome and constipation.

Educational Objectives

1. Review up to date approaches to the medical management of constipation, gastroesophageal reflux, bloating and small bowel bacterial overgrowth.
2. Review the effectiveness/efficacy of current therapies for these GI conditions as well as concerns for potential adverse effects of medical management.
3. Discuss the indications, considerations and subsequent risks following surgical management of GI issues, specifically, anti-reflux surgery, surgery for meconium ileus and DIOS.

Faculty

Christine Hachem M.D.

Asim Maqbool M.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-158-H01-P)

This activity is certified as Knowledge-based CPE

S26 INF/MIC: Year in Review: Influential Papers in Microbiology & Infectious Diseases

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

This is a new session style for the Infection and Microbiology discipline that will focus on papers published within roughly the last year that have influenced or are expected to influence the field of microbiology and infectious diseases in CF. The session speakers will summarize and provide context for a selection of papers in each of four areas: basic science, translational science, pharmacology, and clinical topics.

Educational Objectives

1. Summarize the influential findings in the field, putting them into context with the important gaps in the field they have helped to address.
2. Describe the changes in experimental, translational, or clinical domains that have changed or will be expected to change based on this new information.
3. Discuss the new questions that have arisen in the field based on the papers presented.

Faculty

Lisa Saiman M.D., M.P.H.

Matthew Wargo Ph.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-159-H01-P)

This activity is certified as Knowledge-based CPE

S27 NT: Challenges of Precision Medicine in CF

Release Date: October 7, 2020

Expiration Date: October 23, 2020

Estimated time to complete activity: 80 minutes

This activity is jointly provided by Medical Education Resources and the Cystic Fibrosis Foundation

Target Audience

This activity has been designed to meet the educational needs of physicians, research scientists, nurses, social workers, nutritionists, dietitians, physical therapists, respiratory therapists, pharmacists, psychologists, psychiatrists, research coordinators, geneticists, and other medical professionals involved in CF study and care.

Overview

The use of CFTR modulators in cystic fibrosis is emblematic of precision medicine—with specific CFTR variants being addressed by tailored small molecules. Individual patient response to modulators can be quite variable, although reasons for this heterogeneity remain unknown. Environmental factors, systemic metabolism, tissue levels of drugs, complex CFTR alleles, genetic modifiers, and other factors all may contribute to patient response in vivo. New information in this area and model systems that predict clinical benefit are needed to optimize CF precision therapeutics. The same approaches can be used for improving access among individuals with rarest forms of the disease.

Educational Objectives

1. Discuss the implementation of clinical theratyping in Europe and the United States.
2. Summarize significance of pharmacokinetics and drug metabolism with regard to CFTR modulator response.
3. Explore the importance of CFTR modulators within different organ systems compromised by the disease.

Faculty

Jennifer Guimbellot M.D., Ph.D.

Eric Sorscher M.D.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and the Cystic Fibrosis Foundation. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring activity for a maximum of 1.25 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 1.25 contact hours of continuing nursing education.

Provider approved by the California Board of Registered Nursing, Provider Number 12299, for 1.25 contact hours.

Pharmacy Credit

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-160-H01-P)

This activity is certified as Knowledge-based CPE

Disclaimer and Disclosure of Conflicts of Interest for All Enduring Activities

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources or the Cystic Fibrosis Foundation. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources or the CFF. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Conflicts of Interests

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest. Disclosures of conflicts of interest from the speakers will be provided at the start of every session. MER and CFF content managers have no financial relationships with commercial interests to disclose. Speakers will provide disclosure information in their slides at the beginning of their presentations.